Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult: IV/IM Susceptible infections 1-2 g 8-12 hrly. Max: 12 g/day. Septicaemia Up to 6-8 g/day in 3-4 divided doses. Surgical prophylaxis 1 g 30-90 min before procedure. Gonorrhoea 0.5 g or 1 g as a single dose.
Hypersensitivity to cefotaxime or other cephalosporins.
Special Precautions
Patient w/ history of penicillin allergy and colitis. Renal impairment. Childn. Pregnancy and lactation. Monitoring Parameters Monitor renal function, CBC w/ differential. Observe for signs and symptoms of anaphylaxis during 1st dose.
Adverse Reactions
Rash (maculopapular or erythematous), pruritus, fever, eosinophilia; inflammation, phlebitis, thrombophlebitis (IV); pain, induration, tenderness at inj site (IM); anorexia, diarrhoea, nausea, vomiting, abdominal pain; transient neutropenia, granulocytopenia, leucopenia, eosinophilia or thrombocytopenia; transient increases in BUN and/or serum creatinine concentrations and interstitial nephritis; hepatitis, jaundice, cholestasis; transient increases in serum AST, ALT, LDH, γ-GT, bilirubin, and alkaline phosphatase concentrations; headache, agitation, confusion, fatigue, nocturnal perspiration. Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme.
Potentially Fatal: Clostridium difficile-associated diarrhoea and colitis, arrhythmias, anaphylaxis.
Drug Interactions
Increased risk of nephrotoxicity w/ aminoglycosides. Increased serum concentration w/ probenecid.
CIMS Class
ATC Classification
J01DD01 - cefotaxime ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on cefotaxime from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in